Semaglutide(CSPC)

司美格鲁肽（石药集团）

Report date: 2025/10/20 14:43:35

Base Information

Drug NameSemaglutide(CSPC)
Drug Alias NameHD1916HD-1916
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsOverweightBody WeightObesity +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesCSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCspc Zhongqi Pharmaceutical Technology (Tianjin) Co LtdBeijing Kangchuanglian Biopharmaceutical Technology Research Co LtdCspc Baike (Shandong) Biopharmaceutical Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsOverweightBody WeightObesity +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A